RxDoctor Payments Data

Rosan Sequeda Vargas, MD

General Practice · Bradenton, FLNPI 1174842421

Payments from drug & device makers

$971in general payments, 2019–2025

Across 54 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$401
  • AbbVie$185
  • THD America, Inc.$91
  • Lilly USA, LLC$66
  • Pfizer$50
  • Novo Nordisk$37
  • plus $141 from 6 others

What the payments were for

  • Food & beverage$971100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK25$401
AbbVie(2 entities)11$185
THD America, Inc.1$91
Lilly USA, LLC4$66
Pfizer3$50
Novo Nordisk2$37
Daiichi Sankyo Inc.2$36
Exact Sciences2$35
Gilead1$23
Johnson & Johnson1$18
Amgen1$16
Abbott1$13

How this compares

$971 in reported general payments places this provider in the 75th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$583
Medicare patients
28
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$77,828
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$66,364
JanuviaSitagliptin Phosphate27$39,933
EliquisApixaban35$38,187
JardianceEmpagliflozin20$22,641
Fiasp FlextouchInsulin Aspart (Niacinamide)14$13,038
BrilintaTicagrelor15$10,147
ShingrixVaricella-Zoster Ge/As01b/Pf34$6,792
Albuterol Sulfate HfaAlbuterol Sulfate119$5,679
SymbicortBudesonide/Formoterol Fumarate11$4,848
Ventolin HfaAlbuterol Sulfate49$4,539
Gabapentin188$3,564
Levemir FlexpenInsulin Detemir11$2,440
Atorvastatin Calcium251$1,935
Omeprazole149$1,877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$77,82866 claims
GSKTrelegy Ellipta, Shingrix$401$73,15675 claims
PfizerEliquis$50$38,18735 claims
AbbVieSynthroid$185$98713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,901 general practice providers in Florida.

Other general practice in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →